

FeRiva 21/7®

Rx Only

Dietary Supplement

DESCRIPTION: FeRiva 21/7® tablets for oral administration is a 28-day iron supplement regimen that consists of 21 red, oval-shaped iron tablets and 7 purple, oval-shaped inert tablets. Each red, oval-shaped iron tablet is debossed with "21" and "7" separated by a line in the middle on the top-side of the tablet and blank on the other side. Each purple, oval shaped inert tablet is blank on both sides of the tablet.

Supplement Facts			
Serving Size: 1 tablet			
		% Daily Value	% Daily Value for Pregnant & Lactating Women
Each Red Iron Tablet Contains:			
Vitamin C (as ascorbic acid)	175 mg	194%	146%
Folate (as (6S)-N5-methyl-tetrahydrofolic acid calcium salt (equivalent to 600 mcg of folic acid) and folic acid, USP 400 mcg)	1700 mcg DFE	425%	283%
Vitamin B ₁₂ (as cyanocobalamin)	12 mcg	500%	429%
Iron (as ferrous asparto glycinate) Sumalate®	75 mg	417%	278%
Zinc (as zinc bisglycinate)	10 mg	91%	77%
Succinic Acid	150 mg	†	†
† Daily Value (DV) not established.			
PURPLE PLACEBO TABLETS do not contain ANY vitamins, minerals or other dietary ingredients. Please see OTHER INGREDIENTS section below for the listing of the placebo ingredients.			

OTHER INGREDIENTS (RED IRON TABLETS):

Croscarmellose sodium, dicalcium phosphate, magnesium stearate, microcrystalline cellulose, silicon dioxide and stearic acid. Coating contains: FD&C Red #40, HPMC, Titanium Dioxide and Triacetin.

OTHER INGREDIENTS (PURPLE INERT TABLETS):

Croscarmellose sodium, dicalcium phosphate, magnesium stearate, microcrystalline cellulose, silicon dioxide and stearic acid. Coating contains: FD&C Blue #1, FD&C Red #3, HPMC, Titanium Dioxide and Triacetin.

INDICATIONS: FeRiva 21/7® is a multivitamin/multimineral dietary supplement indicated for use in improving the nutritional status of patients with iron deficiency.

CONTRAINDICATIONS: FeRiva 21/7® is contraindicated in patients with a known hypersensitivity to any of the ingredients. Hemochromatosis and hemosiderosis are contraindicated to iron therapy.

WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. **KEEP THIS PRODUCT OUT OF REACH OF CHILDREN.** In case of accidental overdose, call a doctor or poison control center immediately.

PRECAUTIONS: Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient. Folic acid in doses above 1.0 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress. While prescribing this nutritional supplement for pregnant women, nursing mothers or for women prior to conception, their medical condition and other drugs, herbs and/or supplements consumption should be considered.

ADVERSE REACTIONS: Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

DOSAGE AND ADMINISTRATION: Usual dosage is one tablet daily with or without food or as prescribed by your healthcare provider. The FeRiva 21/7® Tablets blister pack supplies a 28-day course of iron therapy that consists of 21 red iron tablets and 7 purple inert tablets. Take 1 red iron tablet daily for 21 days, followed by 1 purple inert tablet daily for 7 days. After 28 tablets have been taken a new course may be started if prescribed.

HOW SUPPLIED: FeRiva 21/7® tablets blister pack (75854-318-28) contains 21 red iron tablets and 7 purple inert tablets. The listed product number is not a National Drug Code. Instead Avion Pharmaceuticals has assigned a product code formatted according to standard industry practice to meet the formatting requirements of pharmacy and health insurance computer systems.

Keep out of reach of children. Store at 20°C - 25°C (68°F - 77°F); excursions permitted to 15°C - 30°C (59°F - 86°F). [See USP Controlled Room Temperature.]

Avion
PHARMACEUTICALS

Avion Pharmaceuticals, LLC
Alpharetta, GA 30005
1-888-61-AVION
Rev 10/25

Sumalate® is a registered trademark of Albion Laboratories, Inc., covered by one or more claims of U.S. Patent Nos. 6,716,814, 8,007,846, and 8,425,956.

THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE.